Citations

Clear

3314 citation(s) found for "Do, Alexander".

Climbing Up and Down Binding Landscapes through Deep Mutational Scanning of Three Homologous Protein–Protein Complexes
Heyne, Michael , Shirian, Jason , Cohen, Itay , Papo, Niv , Shifman, Julia M. , Radisky, Evette S. , Papo, Niv , Shifman, Julia M , Peleg, Yoav

Mayo Clinic

Journal of the American Chemical Society | October 6, 2021 | Volume: 143 | Issue: 41 | Pages: 17261-17275

10.1021/jacs.1c08707 | PMID 34609866 Get It

Carcinosarcoma of the Ovary
Bolan, Candice W. , Alexander, Lauren F. , LeGout, Jordan D.

Mayo Clinic

No container title available | October 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1148/cases.20211939 Get It

Genome-Wide Association Study of Peripheral Artery Disease
Zuydam, Natalie R. van , Stiby, Alexander, Abdalla, Moustafa , Austin, Erin , McLachlan, Stela , Vlachopoulou, Efthymia, Ahlqvist, Emma , Liao, Chen Di , Sandholm, Niina , Robertson, Neil R., Rayner, Nigel W. , Lindholm, Eero , Sinisalo, Juha , Kallio, Milla , Weiss, Emily , Price, Jackie F. , Paterson, Andrew D. , Klein, Barbara E.K. , Palmer, Colin N.A. , Groop, Per‐Henrik , Groop, Leif , Morris, Andrew P. , Hopewell, Jemma C. , Colhoun, Helen M. , Grétarsdóttir, Sólveig , Þorsteinsdóttir, Unnur , Stefánsson, Kāri , Michael, Mark , Kanninen, Timo, Patrono, Carlo, Nuutila, Pirjo , McKeague, Paul, Steckel-Hamann, Birgit, Gan, Li‐Ming , Nogoceke, Everson, Jablonka, Bernd, Brosnan, Mary-Julia, van Zuydam, Natalie R , Ahlqvist, Emma , Di Liao, Chen , Sandholm, Niina , Forsblom, Carol , Rayner, N William , Lindholm, Eero , Sinisalo, Juha , Perola, Markus , Kallio, Milla , Weiss, Emily , Paterson, Andrew , Salomaa, Veikko , Palmer, Colin N A , McCarthy, Mark I , de Andrade, Mariza , Hopewell, Jemma C , Colhoun, Helen M , Kullo, Iftikhar J , Dahlström, Emma H. , Mahajan, Anubha , McCarthy, Mark I. , Andrade, Mariza de , Kullo, Iftikhar J. , Þorleifsson, Guðmar , Mark, Michael, Thorand, Barbara , Remuzzi, Giuseppe , Dunger, David B. , Shore, Angela C. , Smith, Ulf , Ylä-Herttuala, Seppo , Cobelli, Claudio , Bellazzi, Riccardo , Ferrannini, Ele , Patrono, Carlo, Tortoli, Piero

Mayo Clinic

Circulation: Genomic and Precision Medicine | October 4, 2021 | Volume: 14 | Issue: 5 | Pages: No page available

10.1161/circgen.119.002862 | PMID 34601942 Get It

Background: Peripheral artery disease (PAD) affects >200 million people worldwide and is associated with high mortality and morbidity. We sought to identify genomic variants associated with PAD overall and in the contexts of diabetes and smoking status. Methods: We identified genetic variants associated with PAD and then meta-analyzed with published summary statistics from the Million Veterans Program and UK Biobank to replicate their findings. Next, we ran stratified genome-wide association analysis in ever smokers, never smokers, individuals with diabetes, and individuals with no history of diabetes and corresponding interaction analyses, to identify variants that modify the risk of PAD by diabetic or smoking status. Results: We identified 5 genome-wide significant ( P association ≤5×10 −8 ) associations with PAD in 449 548 (N cases =12 086) individuals of European ancestry near LPA (lipoprotein [a]), CDKN2BAS1 (CDKN2B antisense RNA 1), SH2B3 (SH2B adaptor protein 3) - PTPN11 (protein tyrosine phosphatase non-receptor type 11), HDAC9 (histone deacetylase 9), and CHRNA3 (cholinergic receptor nicotinic alpha 3 subunit ) loci (which overlapped previously reported associations). Meta-analysis with variants previously associated with PAD showed that 18 of 19 published variants remained genome-wide significant. In individuals with diabetes, rs116405693 at the CCSER1 (coiled-coil serine rich protein 1 ) locus was associated with PAD (odds ratio [95% CI], 1.51 [1.32–1.74], P diabetes =2.5×10 −9 , P interactionwithdiabetes =5.3×10 −7 ). Furthermore, in smokers, rs12910984 at the CHRNA3 locus was associated with PAD (odds ratio [95% CI], 1.15 [1.11–1.19], P smokers =9.3×10 −10 , P interactionwithsmoking =3.9×10 −5 ). Conclusions: Our analyses confirm the published genetic associations with PAD and identify novel variants that may influence susceptibility to PAD in the context of diabetes or smoking status.
Racial and Gender Shoulder Arthroplasty Utilization Disparities of High- and Low-Volume Centers in New York State
Markes, Alexander R. , Pareek, Ayoosh , Benjamin, C. , Ward, Derek , Mesfin, Addisu , Benjamin, C.

Mayo Clinic

Journal of Shoulder and Elbow Arthroplasty | October 1, 2021 | Volume: 5 | Issue: No issue available | Pages: No page available

10.1177/24715492211041901 | PMID 34993381 Get It

Introduction The literature has consistently demonstrated utilization disparities in joint replacement procedures, though no studies have evaluated disparities in total shoulder arthroplasty with regard to operative volume. Methods We queried the New York (NY) Statewide Planning and Research Cooperative System (SPARCS) database for 32 410 total shoulder arthroplasties performed between 2009 and 2017. Patients were identified using Clinical Classifications Software code 154 for Non-Hip/Knee Arthroplasty and All Patient Refined-Diagnosis Related Group code 322 for Shoulder. Racial groups included Hispanic, non-Hispanic white, non-Hispanic black, and Other. High-volume centers were facilities that performed 2 standard deviations above the mean annual procedures. Utilization rates were calculated by dividing total shoulder arthroplasties per group by the 2010 NY Census population of that group. The Fisher exact test was used to determine significance. Results Total shoulder arthroplasty utilization increased from 43/100 000 to 73/100 000, two-thirds of which was driven by an increase in white resident utilization. More White residents per 100 000 underwent shoulder arthroplasty than Black, Hispanic, and Other residents per 100 000 residents of their respective race. White residents were 90% more likely than Hispanic residents to undergo total shoulder arthroplasty at high-volume centers ( P = .04). There were no differences in utilization rate regarding operative volume comparing Black or Other residents to White residents. More females underwent total shoulder arthroplasty than males, though there was no difference in utilization rate regarding operative volume. Conclusion Though total shoulder arthroplasty utilization nearly doubled, disparities persisted across gender and minority groups particularly in Hispanic utilization as White residents were 90% more likely than Hispanic residents to undergo shoulder arthroplasty at high-volume centers.
Trends in Testosterone Prescriptions for Older Men Enrolled in Commercial Insurance and Medicare Advantage
Everhart, Alexander , Harper, Katrina , Jeffery, Molly M. , Levin, Zachary , Morden, Nancy E., Sankar, Ashwini , Karaca‐Mandic, Pinar , Jeffery, Molly Moore

Mayo Clinic

JAMA Network Open | September 29, 2021 | Volume: 4 | Issue: 9 | Pages: e2127349

10.1001/jamanetworkopen.2021.27349 | PMID 34586370 Get It

Free Flap Coverage for Complex Primary and Revision Total Knee Arthroplasty
Athey, Alexander G., Carlsen, Brian T. , Perry, Kevin I. , Moran, Steven L. , Wyles, Cody C. , Houdek, Matthew T.

Mayo Clinic

Plastic & Reconstructive Surgery | September 29, 2021 | Volume: 148 | Issue: 5 | Pages: 804e-810e

10.1097/prs.0000000000008452 | PMID 34586098 Get It

Background: Free flap coverage in the setting of a total knee arthroplasty is rare. The purpose of the current study was to evaluate the outcome of patients who underwent a free flap to assist with soft-tissue coverage following a complex total knee arthroplasty. Methods: The authors used their institutional total joint registry to retrospectively review patients undergoing a free soft-tissue flap in the setting of complex primary and revision total knee arthroplasty. Among 29,069 primary and 6433 revision total knee arthroplasties from 1994 to 2017, eight (0.02 percent) required a free flap for wound coverage. This included three primary total knee arthroplasties (0.01 percent) for posttraumatic arthritis and five revision total knee arthroplasties (0.07 percent) in the setting of infection. Median follow-up was 4 years. Results: Free flaps included vertical rectus abdominis (n = 3), anterior lateral thigh (n = 2), latissimus (n = 2), and transverse rectus abdominis (n = 1). There were no total flap losses; however, one patient required additional skin grafting. Reoperation occurred in six patients, of which four were revisions of the total knee arthroplasty for infection (n = 2) and tibial component loosening (n = 2). One patient ultimately underwent transfemoral amputation for persistent infection. Following reconstruction, there was improvement in the median Knee Society Score (49 versus 82; p = 0.03) and total range of motion between preoperative and postoperative assessments (70 degrees versus 85 degrees; p = 0.14). Conclusion: Free flap coverage in the setting of total knee arthroplasty was associated with a high rate of reoperation; however, the limb was able to be preserved in the majority of patients, with a reasonable functional outcome. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
No Difference in Neck Pain or Health-Related Quality Measures Between Patients With or Without Degenerative Cervical Spondylolisthesis
Kaye, I. David , Sebastian, Arjun S. , Wagner, Scott C. , Semenza, Nicholas C. , Bowles, Daniel R. , Schroeder, Gregory D. , Kepler, Chris K., Woods, Barret I., Rihn, Jeff, Anderson, David Greg, Hilibrand, Alan S. , Kepler, Christopher K. , Kaye, Ian David , Semenza, Nicholas , Radcliff, Kris E. , Kurd, Mark F. , Vaccaro, Alexander R.

Mayo Clinic

Global Spine Journal | September 27, 2021 | Volume: 13 | Issue: 6 | Pages: 1641-1645

10.1177/21925682211046906 | PMID 34570993 Get It

Study Design This study is a retrospective case control. Objectives This study aims to determine whether cervical degenerative spondylolisthesis (DS) is associated with increased baseline neck/arm pain and inferior health quality states compared to a similar population without DS. Methods Patient demographics, pre-operative radiographs, and baseline PROMs were reviewed for 315 patients undergoing anterior cervical decompression and fusion (ACDF) with at least 1 year of follow-up. Patients were categorized based on the presence (S) or absence of a spondylolisthesis (NS). Statistically significant variables were further explored using multiple linear regression analysis. Results 49/242 (20%) patients were diagnosed with DS, most commonly at the C4–5 level (27/49). The S group was significantly older than the NS group (58.0 ± 10.7 vs 51.9 ± 9.81, P = .001), but otherwise, no demographic differences were identified. Although a higher degree of C2 slope was found among the S cohort (22.5 ± 8.63 vs 19.8 ± 7.78, P = .044), no differences were identified in terms of preoperative visual analogue scale (VAS) neck pain or NDI. In the univariate analysis, the NS group had significantly increased VAS arm pain relative to the S group (4.93 ± 3.16 vs 3.86 ± 3.30, P = .045), which was no longer significant in the multivariate analysis. Conclusions Although previous reports have suggested an association between cervical DS and neck pain, we could not associate the presence of DS with increased baseline neck or arm pain. Instead, DS appears to be a relatively frequent (20% in this series) age-related condition reflecting radiographic, rather than necessarily clinical, disease.
Trends in Diagnosis and Treatment of Metastatic Cancer in the United States
Lehrer, Eric J. , Stoltzfus, Kelsey C. , Walter, Vonn , Louie, Alexander V. , Walter, Vonn , Jones, Brianna M. , Gusani, Niraj J. , Wang, Ming , Trifiletti, Daniel M. , Siva, Shankar , Zaorsky, Nicholas G.

Mayo Clinic

American Journal of Clinical Oncology | September 24, 2021 | Volume: 44 | Issue: 11 | Pages: 572-579

10.1097/coc.0000000000000866 | PMID 34560720 Get It

Objectives: Metastatic cancer has historically been considered fatal; however, there is a paucity of evidence characterizing the epidemiology of incidence, treatment, and outcomes in these patients. Materials and Methods: Incidence rates, annual percent change (APC), descriptive epidemiological statistics, and odds ratios for survival were calculated using registry data from the Surveillance, Epidemiology, and End Results (SEER) and the National Cancer Database (NCDB), 1998 to 2015. Results: There were a total of 1,055,860 patients with metastatic cancer. The most frequent primary cancers were lung (42.6%), colorectal (9.5%), and ovarian (5.5%). Metastatic lung and colorectal cancer incidence decreased, APC: −1.57 (P<0.001) and APC: −1.48 (P<0.001), respectively; metastatic pancreatic cancer incidence increased, APC: 0.62 (P=0.001). The use of local therapies decreased for almost all sites, and the use of systemic therapies increased across multiple sites: single-agent chemotherapy in kidney (2.54% increase/year), female breast (1.14% increase/year), and prostate cancer (1.08% increase/year); multiagent chemotherapy, most notably in pancreas (2.23% increase/year), uterus (1.81% increase/year), and colorectal cancer (1.54% increase/year). Increased utilization of immunotherapy was observed across the majority of sites, most notably in melanoma (2.14% increase/year). Patients diagnosed from 2006 to 2010 had 17.4% higher odds of surviving at least 60 months compared with 1998 to 2002. Conclusions: In this study, metastatic disease has been shown to have unique epidemiological patterns, and survival has improved. Continued research on metastatic disease is important in understanding and addressing the distinct health concerns of this population.
Physician Network Connections Associated With Faster De-Adoption of Dronedarone for Permanent Atrial Fibrillation
Stecher, Chad , Everhart, Alexander , Smith, Laura Barrie , Jena, Anupam B. , Ross, Joseph S. , Desai, Nihar R. , Shah, Nilay D. , Karaca‐Mandic, Pinar , Jena, Anupam B , Shah, Nilay , Ross, Joseph S , Everhart, Alexander O

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | September 24, 2021 | Volume: 14 | Issue: 10 | Pages: No page available

10.1161/circoutcomes.121.008040 | PMID 34555928 Get It

Background: Physicians’ professional networks are an important source of new medical information and have been shown to influence the adoption of new treatments, but it is unknown how physician networks impact the de-adoption of harmful practices. Methods: We analyzed changes in physicians’ use of dronedarone after the PALLAS trial (Palbociclib Collaborative Adjuvant Study; November 2011) showed that dronedarone increased the risk of death from cardiovascular events among patients with permanent atrial fibrillation. Deidentified administrative claims from the OptumLabs Data Warehouse were combined with physicians’ demographic information from the Doximity database and publicly available data on physicians’ patient-sharing relationships compiled by the Centers for Medicare and Medicaid Services. We used a linear probability model with an interrupted linear time trend specification to model the impact of the PALLAS trial on physicians’ dronedarone usage between 2009 and 2014. Results: Before the PALLAS trial, the use of dronedarone was increasing by 0.22 percentage points per quarter (95% CI, 0.19–0.25) in our Medicare Advantage sample (N=343 429 patient-quarter observations) and 0.63 percentage points per quarter (95% CI, 0.52–0.75) in our commercially insured sample (N=44 402 patient-quarter observations). After the PALLAS trial and subsequent United States Food and Drug Administration black box warning, physicians in the Medicare Advantage sample with an above-median number of network connections to other physicians decreased their quarterly usage of dronedarone by 0.12 percentage points more per quarter (95% CI, −0.20 to −0.04; P =0.031) than physicians with equal to or below the median number of network connections. Similar patterns existed in the commercially insured sample ( P =0.0318). Conclusions: After controlling for a wide range of patient, physician, and geographic characteristics, physicians with a greater number of network connections were faster de-adopters of dronedarone for patients with permanent atrial fibrillation after the PALLAS trial and subsequent United States Food and Drug Administration black box warning detailed the harmfulness of dronedarone for these patients. Policies for improving physicians’ responsiveness to new medical information should consider utilizing the influence of these important professional network relationships.
Functional succinate dehydrogenase deficiency is a common adverse feature of clear cell renal cancer
Aggarwal, Ritesh K. , Luchtel, Rebecca A. , Machha, Venkata R. , Tischer, Alexander , Zou, Yiyu , Ashai, Nadia , Ramachandra, Nandini , Albanese, Joseph , Yang, Jung‐In , Aluri, Srinivas , Gordon, Shanisha, Aboumohamed, Ahmed , Gartrell, Benjamin A. , Hafizi, Sassan , Pullman, James , Shenoy, Niraj , Yang, Jung-In , Aluri, Srinivas , Aboumohamed, Ahmed , Hafizi, Sassan , Shenoy, Niraj , Tischer, Alexander , Pradhan, Kith , Wang, Xiaoyang

Mayo Clinic

Proceedings of the National Academy of Sciences | September 22, 2021 | Volume: 118 | Issue: 39 | Pages: No page available

10.1073/pnas.2106947118 | PMID 34551979 Get It

Significance This study demonstrates that underexpression of succinate dehydrogenase (SDH) subunits resulting in accumulation of oncogenic succinate is a common, adverse, epigenetic modulating feature in clear cell renal cell carcinoma (ccRCC), during pathogenesis and progression. The study sheds light on the mechanisms of down-regulation of SDH subunits in ccRCC and deciphers the consequent oncogenic effects. It shows that functional SDH deficiency is a common feature of ccRCC (∼80% of all kidney cancers), and not just limited to the 0.05 to 0.5% of kidney cancers with germline SDH mutations.